Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of KCONVAC in Healthy Children and Adolescents
NCT05003466Phase 2Unknown
- Sponsor
- Shenzhen Kangtai Biological Products
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing KCONVAC with Placebo (2 arms). Primary endpoints: Seroconversion rate of SARS-CoV-2 neutralizing antibody and Geometric mean titer of SARS-CoV-2 neutralizing antibody. Status: unknown.
02
Drugs
KCONVAC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05003466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003466.